Antibody engineering and modification technologies
- 1 June 2007
- journal article
- review article
- Published by Elsevier BV in Biomolecular Engineering
- Vol. 24 (2), 201-215
- https://doi.org/10.1016/j.bioeng.2007.03.004
Abstract
No abstract availableThis publication has 111 references indexed in Scilit:
- Breaking the one antibody–one target axiomProceedings of the National Academy of Sciences of the United States of America, 2006
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006
- Isolation of anti-CD22 Fv with high affinity by Fv display on human cellsProceedings of the National Academy of Sciences, 2006
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targetingProceedings of the National Academy of Sciences, 2006
- Engineering novel binding proteins from nonimmunoglobulin domainsNature Biotechnology, 2005
- Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levelsNature Biotechnology, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005